Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
PR Newswire•29/09/2026•08:00 ET
0
Whiz Insights
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher PR Newswire
Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter
Get started
Create a free account to read the full story.